Fig. 7

Immunohistochemistry staining determined MMP12, MMP9, CD36, and FABP4 expression in tissues of patients with NSCLC. A Compared with the adjacent non-cancerous lung tissues of patients taking atorvastatin, MMP12 and MMP9 were highly expressed in the tumor stroma of LUAD. CD36 presented a cell membrane pattern of staining, and the expression levels of CD36 in LUAD were higher compared with adjacent non-cancerous lung tissues in patients who took atorvastatin. FABP4 showed nuclear and cytoplasmic staining patterns, and the expression levels of CD36 in LUAD of patients taking atorvastatin was higher compared with adjacent noncancerous lung tissues. B Expression of MMP12, MMP9, CD36, and FABP4 expression in LUSC tissue samples and corresponding adjacent non-cancerous lung tissues. In patients taking atorvastatin, MMP12, MMP9, CD36, and FABP4 were highly expressed in the LUSC, butwere low expressed in the adjacent non-cancerous lung tissues. The intensity of immunohistochemical staining was analyzed using ImageJ 2.0 software. ^*p < 0.05, ^**p < 0.01 vs. control. ^##p < 0.01 vs. ATV. Scale bars = 50 μm